Illumina is reducing its forecast for this year’s financial performance and cutting $100 million in spending because China barred sales of the company’s gene-sequencing machines. San Diego ...

The firm increased its portfolio allocation in ILMN by 34.84% over the last quarter. Illumina Background Information (This description is provided by the company.) Illumina is improving human ...

11 analysts have expressed a variety of opinions on Illumina ILMN over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...

Illumina navigates competition and geopolitical risks with improved margins and strong cash flow. Read my analysis of ILMN ...

Gene-sequencing giant Illumina is laying off 96 employees from its San Diego headquarters, according to paperwork filed with the state. This workforce reduction comes at a time when Illumina is ...

Illumina reported Q3 2024 revenue of $1.08 billion -- in line with analysts' consensus estimate. Non-GAAP EPS was $1.14, exceeding the $0.879 consensus and indicating strong cost control. Despite ...

The Chinese government took its economic sanctions against San Diego-based Illumina a step further Tuesday by banning the gene-sequencing company from importing its machines to the country.

Illumina restored its profitability well ... that Roche is expected to launch a DNA sequencer with a technological background related to its 2020 acquisition of Stratos Genomics.

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, has been named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow ...